ABL1 and acute lymphoblastic leukemia: Patients with newly diagnosed Ph + ALL (n = 13), Ph‐like ALL (n = 1, with RCSD1‐ABL1 fusion gene), relapsed Ph + ALL (n = 3), and relapsed Ph‐like ALL (n = 2; one patient relapsed from the newly diagnosed cohort, one with NUP214‐ABL1) were treated with the combination of blinatumomab and a TKI.